Unable to display view head.php file not found.<div id='slide_area'>
  <div class='slide'>
    <center>
    <table class='layout' width='700'>
      <tr>
        <td style='vertical-align: middle;' width='135'>
          <center>
                    <a href="figure.php?speaker=barter&figure=22" class='slide_link buttonify center nextprev_button'>&laquo;&nbsp;Prev</a>
                    </center>
        </td>
        <td width='420'>
          <div class='slide_image'>
                                                <a href="figure_images/barter/figure23_large.png" class="overlay" title="Barter - Figure 23 - dal-OUTCOMES">
                                        <img src="figure_images/barter/figure23_w420.png" border='0'>
                                      </a>
                      </div>
        </td>
        <td style='vertical-align: middle;' width='135'>
          <center>
                    <a href="figure.php?speaker=barter&figure=24" class='slide_link buttonify center nextprev_button'>Next&nbsp;&raquo;</a>
                    </center>
        </td>
      </tr>
      <tr>
        <td>&nbsp;</td>
        <td>
                    <div class='slide_layout_control'>
                            <div id="slide_audio" class="jp-jplayer"></div><!-- DOM anchor for jPlayer, not styled -->
        <div class="jp-audio">
          <div class="jp-type-single">
            <div id="jp_interface_1" class="jp-interface">
              <ul class="jp-controls">
                <li><a href="#" class="jp-play" tabindex="1">play</a></li>
                <li><a href="#" class="jp-pause" tabindex="1">pause</a></li>
                <li><a href="#" class="jp-stop" tabindex="1">stop</a></li>
                <li><a href="#" class="jp-mute" tabindex="1">mute</a></li>
                <li><a href="#" class="jp-unmute" tabindex="1">unmute</a></li>
              </ul>
              <div class="jp-progress">
                <div class="jp-seek-bar">
                  <div class="jp-play-bar"></div>
                </div>
              </div>
              <div class="jp-volume-bar">
                <div class="jp-volume-bar-value"></div>
              </div>
              <div class="jp-current-time"></div>
              <div class="jp-duration"></div>
            </div>
            <div id="jp_playlist_1" class="jp-playlist">
            </div>
          </div>
        </div>
        <script type="text/javascript">
          $(document).ready(function(){
            $("#slide_audio").jPlayer({
              ready: function () {
                var jp_conf = {}; 
                jp_conf['oga'] = 'audio/barter/figure23_audio.ogg';
                jp_conf['mp3'] = 'audio/barter/figure23_audio.mp3';
                $(this).jPlayer("setMedia", jp_conf);
              },
              swfPath: "//www.webedcafe.com/extern/program_media/lib/jQuery.jPlayer.2.0.0",
              solution: "html,flash",
              supplied: "oga, mp3"
              , errorAlerts: false //dies on videoPlay not being found otherwise, stupidly
              , warningAlerts: true
            });
          });
        </script>
                    </div>
        </td>
        <td>&nbsp;</td>
      </tr>
    </table>
    </center>
  </div>    
</div><!-- end slide area -->

<div class='with_figure_content'>
<div class='transcript'>
  <div class='right'>
<a href="printable.php?speaker=barter&figure=23" class="print_link buttonify" target_orig="_blank" style=''>Print This Page</a>
</div>
<h2>Barter - Figure 23 - dal-OUTCOMES</h2>

  <p>
Given all of the above, there are 3 further trials currently underway, assessing a strategy

of CETP inhibition:
<ul>
  <li>dal-OUTCOMES</li>
  <li>DEFINE</li>
  <li>REVEAL: HPS3-TIMI 55</li>
</ul>

The first trial, dal-OUTCOMES, is with dalcetrapib (Roche), another member of the

CETP inhibitor class, as shown in this <b>Figure</b>. This trial is now close to completion,

having enrolled 15,600 patients who were 4-12 weeks post acute coronary syndrome

(ACS) event, or acute myocardial infarction (MI). They were all on statin therapy to

achieve optimal LDL levels, which was maintained throughout the study, and half were

randomized to receive dalcetrapib at a 600 mg dose, with a planned follow-up of 2.5

years, but with everybody followed up for at least 2 years and 80% reaching the 2.5

years. dal-OUTCOMES is an event-driven trial, and it will continue until the required

number of events has been reached, a composite endpoint of various cardiovascular

events typical of most trials of this kind.
</p>
<span class='figuretext_source_identifier'>
  <span class="author">Barter P.</span>
  <span class="publication">J Clin Lipidol.</span>
  <span class="identifier">2011; 5(6).</span>
</span>
</div>
</div>
Unable to display view foot.php file not found.